Full-Field Stimulus Test for Visual Function Assessment in Ultra-Low Vision with Retinitis Pigmentosa
Ophthalmology Science · 2026-11 · 101458
DOI: 10.1016/j.xops.2026.101458 ↗Kurz gefasst
Fachartikel in der Zeitschrift Ophthalmology Science, 2026-11. Verfasst von Lizhu Yang und 11 weiteren Autor:innen. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
Purpose
Assessing visual function in patients with ultralow vision (ULV), particularly those with retinitis pigmentosa (RP), remains a significant challenge in therapeutic development. Full-field stimulus test (FST) provides a quantitative measure of retinal light sensitivity and may serve as a valuable clinical endpoint. We investigated FST in ULV RP by examining its associations with functional measures and daily activity–based tasks.
Design
Observational, cross-sectional study.
Participants
Patients with RP and visual acuity in the worse-seeing eye below counting fingers (CF) were enrolled.
Methods
After dilation and 45-minute dark adaptation, FST was performed monocularly with brief full-field white-light flashes across three visits. Visual acuity was classified into four groups: no light perception (NLP), light perception (LP), hand motion (HM), and CF or better. We assessed functional vision using two tabletop object-recognition and exploration tasks, two mobility tasks, and three vision-related questionnaires. FST thresholds were compared across visual acuity groups, and associations with functional outcomes were analyzed. Main Outcome Measures FST thresholds and their associations with functional vision outcomes.
Results
Thirty-five patients (70 eyes; median age, 62 years, range 39–84) were included. Median FST thresholds (log cd⋅s/m 2 ) by visual acuity group were as follows: NLP, 1.13 (-0.63–2.54); LP, -0.27 (-2.70–2.91); HM, -1.13 (-6.24–0.51); CF or better, -2.82 (-5.67–-1.73) (p < 0.001). Measurable FST thresholds were obtained in 9 of 14 NLP eyes (64.3%). FST thresholds showed significant correlations with tabletop performance (ρ = –0.70 to –0.46) and mobility performance (ρ = –0.65), whereas no significant association was observed with questionnaire scores. Test–retest variability across three visits showed no systematic bias, with a coefficient of repeatability of ±0.66 to ±0.82 log cd·s/m 2 . ROC analyses identified FST cutoffs of –1.75 to –0.87 log cd·s/m 2 at which patients first achieved nonzero functional task performance.
Conclusions
FST quantifies residual visual function in ULV RP and correlates strongly with performance-based measures of functional vision in daily life. These findings support FST as a clinically meaningful endpoint for therapeutic trials in advanced RP and other severe visual impairments and highlight the value of anchoring FST thresholds to functional task performance.
Förderung
- Japan Agency for Medical Research and Development
Zitieren
APA
Yang, L., Katada, Y., Fujinami, K., Yamamoto, S., Fukuda, K., Shinojima, A., Tomita, Y., Ban, N., Kunimi, H., Shinoda, H., Negishi, K., & Kurihara, T. (2026). Full-Field Stimulus Test for Visual Function Assessment in Ultra-Low Vision with Retinitis Pigmentosa. Ophthalmology Science, 101458. https://doi.org/10.1016/j.xops.2026.101458
Vancouver
Yang L, Katada Y, Fujinami K, Yamamoto S, Fukuda K, Shinojima A, et al. Full-Field Stimulus Test for Visual Function Assessment in Ultra-Low Vision with Retinitis Pigmentosa. Ophthalmology Science. 2026:101458. doi:10.1016/j.xops.2026.101458
BibTeX
@article{Yang2026,
author = {Yang, Lizhu and Katada, Yusaku and Fujinami, Kaoru and Yamamoto, Shiori and Fukuda, Konomi and Shinojima, Ari and Tomita, Yohei and Ban, Norimitsu and Kunimi, Hiromitsu and Shinoda, Hajime and Negishi, Kazuno and Kurihara, Toshihide},
title = {Full-Field Stimulus Test for Visual Function Assessment in Ultra-Low Vision with Retinitis Pigmentosa},
journal = {Ophthalmology Science},
year = {2026},
pages = {101458},
doi = {10.1016/j.xops.2026.101458}
}
EUVIMED